vs
HAEMONETICS CORP（HAE）与3M（MMM）财务数据对比。点击上方公司名可切换其他公司
3M的季度营收约是HAEMONETICS CORP的17.8倍（$6.0B vs $339.0M），HAEMONETICS CORP净利率更高（13.2% vs 10.8%，领先2.4%），3M同比增速更快（1.3% vs -2.7%），3M自由现金流更多（$2.0B vs $87.2M），过去两年HAEMONETICS CORP的营收复合增速更高（0.4% vs -1.8%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
3M是美国知名跨国综合企业，业务覆盖工业、劳动者安全防护、消费品等多个领域，总部位于圣保罗郊区的枫木市。公司现有超6万款产品，涵盖胶粘剂、研磨材料、防火防护产品、个人防护装备、窗膜、车漆保护膜、电子连接绝缘材料、汽车养护产品、光学膜等品类。
HAE vs MMM — 直观对比
营收规模更大
MMM
是对方的17.8倍
$339.0M
营收增速更快
MMM
高出4.0%
-2.7%
净利率更高
HAE
高出2.4%
10.8%
自由现金流更多
MMM
多$1.9B
$87.2M
两年增速更快
HAE
近两年复合增速
-1.8%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $6.0B |
| 净利润 | $44.7M | $653.0M |
| 毛利率 | 59.7% | 40.7% |
| 营业利润率 | 19.9% | 23.2% |
| 净利率 | 13.2% | 10.8% |
| 营收同比 | -2.7% | 1.3% |
| 净利润同比 | 19.3% | -41.5% |
| 每股收益（稀释后） | $0.95 | $1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAEMMM
| Q1 26 | — | $6.0B | ||
| Q4 25 | $339.0M | $6.1B | ||
| Q3 25 | $327.3M | $6.5B | ||
| Q2 25 | $321.4M | $6.3B | ||
| Q1 25 | $330.6M | $6.0B | ||
| Q4 24 | $348.5M | $6.0B | ||
| Q3 24 | $345.5M | $6.3B | ||
| Q2 24 | $336.2M | $6.3B |
净利润HAEMMM
| Q1 26 | — | $653.0M | ||
| Q4 25 | $44.7M | $577.0M | ||
| Q3 25 | $38.7M | $834.0M | ||
| Q2 25 | $34.0M | $723.0M | ||
| Q1 25 | $58.0M | $1.1B | ||
| Q4 24 | $37.5M | $728.0M | ||
| Q3 24 | $33.8M | $1.4B | ||
| Q2 24 | $38.4M | $1.1B |
毛利率HAEMMM
| Q1 26 | — | 40.7% | ||
| Q4 25 | 59.7% | 33.6% | ||
| Q3 25 | 59.5% | 41.8% | ||
| Q2 25 | 59.8% | 42.5% | ||
| Q1 25 | 58.4% | 41.6% | ||
| Q4 24 | 55.5% | 51.7% | ||
| Q3 24 | 54.2% | 42.1% | ||
| Q2 24 | 52.0% | 42.9% |
营业利润率HAEMMM
| Q1 26 | — | 23.2% | ||
| Q4 25 | 19.9% | 13.0% | ||
| Q3 25 | 17.9% | 22.2% | ||
| Q2 25 | 16.8% | 18.0% | ||
| Q1 25 | 21.6% | 20.9% | ||
| Q4 24 | 16.9% | 12.2% | ||
| Q3 24 | 15.0% | 20.9% | ||
| Q2 24 | 11.8% | 20.3% |
净利率HAEMMM
| Q1 26 | — | 10.8% | ||
| Q4 25 | 13.2% | 9.4% | ||
| Q3 25 | 11.8% | 12.8% | ||
| Q2 25 | 10.6% | 11.4% | ||
| Q1 25 | 17.5% | 18.7% | ||
| Q4 24 | 10.8% | 12.1% | ||
| Q3 24 | 9.8% | 21.8% | ||
| Q2 24 | 11.4% | 18.3% |
每股收益（稀释后）HAEMMM
| Q1 26 | — | $1.23 | ||
| Q4 25 | $0.95 | $1.07 | ||
| Q3 25 | $0.81 | $1.55 | ||
| Q2 25 | $0.70 | $1.34 | ||
| Q1 25 | $1.17 | $2.04 | ||
| Q4 24 | $0.74 | $1.33 | ||
| Q3 24 | $0.66 | $2.48 | ||
| Q2 24 | $0.74 | $2.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $3.7B |
| 总债务越低越好 | $1.2B | $10.9B |
| 股东权益账面价值 | $911.5M | $3.3B |
| 总资产 | $2.5B | $35.4B |
| 负债/权益比越低杠杆越低 | 1.34× | 3.29× |
8季度趋势，按日历期对齐
现金及短期投资HAEMMM
| Q1 26 | — | $3.7B | ||
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — |
总债务HAEMMM
| Q1 26 | — | $10.9B | ||
| Q4 25 | $1.2B | $12.6B | ||
| Q3 25 | $1.2B | $12.6B | ||
| Q2 25 | $1.2B | $13.1B | ||
| Q1 25 | $1.2B | $13.5B | ||
| Q4 24 | — | $13.0B | ||
| Q3 24 | — | $13.2B | ||
| Q2 24 | — | $13.1B |
股东权益HAEMMM
| Q1 26 | — | $3.3B | ||
| Q4 25 | $911.5M | $4.7B | ||
| Q3 25 | $849.2M | $4.6B | ||
| Q2 25 | $882.3M | $4.3B | ||
| Q1 25 | $820.8M | $4.5B | ||
| Q4 24 | $906.9M | $3.8B | ||
| Q3 24 | $878.9M | $4.6B | ||
| Q2 24 | $905.4M | $3.9B |
总资产HAEMMM
| Q1 26 | — | $35.4B | ||
| Q4 25 | $2.5B | $37.7B | ||
| Q3 25 | $2.4B | $37.6B | ||
| Q2 25 | $2.5B | $38.0B | ||
| Q1 25 | $2.5B | $40.0B | ||
| Q4 24 | $2.5B | $39.9B | ||
| Q3 24 | $2.5B | $40.9B | ||
| Q2 24 | $2.5B | $43.4B |
负债/权益比HAEMMM
| Q1 26 | — | 3.29× | ||
| Q4 25 | 1.34× | 2.68× | ||
| Q3 25 | 1.44× | 2.72× | ||
| Q2 25 | 1.39× | 3.06× | ||
| Q1 25 | 1.49× | 3.02× | ||
| Q4 24 | — | 3.40× | ||
| Q3 24 | — | 2.84× | ||
| Q2 24 | — | 3.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | — |
| 自由现金流经营现金流 - 资本支出 | $87.2M | $2.0B |
| 自由现金流率自由现金流/营收 | 25.7% | 33.6% |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | 2.09× | — |
| 过去12个月自由现金流最近4个季度 | $308.1M | $3.7B |
8季度趋势，按日历期对齐
经营现金流HAEMMM
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $1.6B | ||
| Q3 25 | $111.3M | $1.8B | ||
| Q2 25 | $17.4M | $-954.0M | ||
| Q1 25 | $116.6M | $-79.0M | ||
| Q4 24 | $43.8M | $1.8B | ||
| Q3 24 | $48.8M | $-1.8B | ||
| Q2 24 | $-27.4M | $1.0B |
自由现金流HAEMMM
| Q1 26 | — | $2.0B | ||
| Q4 25 | $87.2M | $1.3B | ||
| Q3 25 | $106.3M | $1.5B | ||
| Q2 25 | $13.6M | $-1.2B | ||
| Q1 25 | $100.9M | $-315.0M | ||
| Q4 24 | $35.2M | $1.5B | ||
| Q3 24 | $39.4M | $-2.0B | ||
| Q2 24 | $-33.1M | $752.0M |
自由现金流率HAEMMM
| Q1 26 | — | 33.6% | ||
| Q4 25 | 25.7% | 21.8% | ||
| Q3 25 | 32.5% | 23.6% | ||
| Q2 25 | 4.2% | -18.3% | ||
| Q1 25 | 30.5% | -5.3% | ||
| Q4 24 | 10.1% | 25.4% | ||
| Q3 24 | 11.4% | -32.3% | ||
| Q2 24 | -9.8% | 12.0% |
资本支出强度HAEMMM
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 4.0% | ||
| Q3 25 | 1.5% | 3.3% | ||
| Q2 25 | 1.2% | 3.3% | ||
| Q1 25 | 4.7% | 4.0% | ||
| Q4 24 | 2.5% | 4.8% | ||
| Q3 24 | 2.7% | 3.9% | ||
| Q2 24 | 1.7% | 4.3% |
现金转化率HAEMMM
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | 2.74× | ||
| Q3 25 | 2.88× | 2.11× | ||
| Q2 25 | 0.51× | -1.32× | ||
| Q1 25 | 2.01× | -0.07× | ||
| Q4 24 | 1.17× | 2.50× | ||
| Q3 24 | 1.44× | -1.30× | ||
| Q2 24 | -0.71× | 0.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
MMM
| Safety and Industrial business segment | $2.9B | 49% |
| Transportation and Electronics business segment | $1.8B | 31% |
| Consumer business segment | $1.1B | 19% |
| Corporate | $121.0M | 2% |
